Literature DB >> 1331411

Intermediate efficacy mu opioids: examination of their morphine-like stimulus effects and response rate-decreasing effects in morphine-tolerant rats.

M J Picker1, R M Craft, S S Negus, K R Powell, S R Mattox, S R Jones, B K Hargrove, L A Dykstra.   

Abstract

The present study examined the effects of morphine, the intermediate efficacy mu opioids (-)-pentazocine, (-)-metazocine, proxorphan, levallorphan, (-)-NANMY (N-allylnormetazocine) and (-)-cyclazocine, and the mu antagonist naloxone 1) in rats responding under a FR (fixed-ratio) 30 schedule before, during and after a chronic morphine regimen, and 2) in rats trained to discriminate 10.0 [10-MS (morphine sulfate)] or 3.0 mg/kg (3-MS) of morphine from saline. Under the FR30 schedule, chronic administration of morphine produced tolerance to morphine's rate-decreasing effects and conferred cross-tolerance to (-)-metazocine, proxorphan and (-)-pentazocine. However, the effects of these intermediate efficacy mu opioids could be differentiated from those of morphine on the basis of their 1) shallow dose-effect curves, and 2) large differences in the degree to which tolerance developed in individual rats. In the drug discrimination procedure, (-)-metazocine, proxorphan and (-)-pentazocine produced high levels of substitution for the 3-MS stimulus and intermediate levels for the 10-MS stimulus. In contrast to the pattern of substitution observed with morphine in the 10-MS group, the effects of these drugs were characterized by 1) shallow dose-effect curves, 2) large individual differences in the lowest dose of each drug that substituted completely for the 10-MS stimulus and 3) the failure to obtain complete substitution for the 10-MS stimulus in all of the rats tested. The behavioral profile obtained with the intermediate efficacy mu opioids (-)-NANM, levallorphan and (-)-cyclazocine was indicative of opioids with intrinsic efficacy lower than that of (-)-pentazocine, (-)-metazocine and proxorphan. Under the FR30 schedule, chronic administration of morphine produced an enhanced sensitivity to the rate-decreasing effects of (-)-NANM and levallorphan but not (-)-cyclazocine. In the drug discrimination procedure, (-)-NANM, levallorphan and (-)-cyclazocine produced high levels of substitution for the 3-MS stimulus and low levels for the 10-MS stimulus. Like naloxone, these drugs produced a dose-related attenuation of the 10-MS stimulus. The results of the present study suggest that the relative order of intrinsic efficacy among the opioids tested is: morphine > (-)-metazocine = (-)-pentazocine = proxorphan > (-)-cyclazocine = levallorphan = (-)-NANM > naloxone.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331411

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Patterns of nicotinic receptor antagonism: nicotine discrimination studies.

Authors:  Emily M Jutkiewicz; Emily A Brooks; Adam D Kynaston; Kenner C Rice; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2011-07-05       Impact factor: 4.030

2.  Opiate states of memory: receptor mechanisms.

Authors:  L A Bruins Slot; F C Colpaert
Journal:  J Neurosci       Date:  1999-12-01       Impact factor: 6.167

Review 3.  Role of training dose in drug discrimination: a review.

Authors:  Ian P Stolerman; Emma Childs; Matthew M Ford; Kathleen A Grant
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

4.  Antagonism of the discriminative stimulus effects of the kappa-opioid agonist spiradoline.

Authors:  S G Holtzman; G F Steinfels
Journal:  Psychopharmacology (Berl)       Date:  1994-11       Impact factor: 4.530

5.  Discriminative stimulus effects of midazolam and abecarnil in rats treated chronically with diazepam or abecarnil.

Authors:  D A Lytle; M W Emmett-Oglesby; D N Stephens
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

6.  Acute pain-related depression of operant responding maintained by social interaction or food in male and female rats.

Authors:  A N Baldwin; M L Banks; S A Marsh; E A Townsend; M Venniro; Y Shaham; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2022-01-19       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.